Preclinical research indicates that HDAC inhibitors, such as trichostatin A, enhance the acetylation of the NFE2L2 promoter in murine models of osteoarthritis, thereby restoring Nrf2-driven antioxidant defenses [160,161]. The gene discussed is NFE2L2; the disease is osteoarthritis.